Biotechna and SyVento Biotech entered into a strategic partnership for project „Design and development of nanoparticle RNA based drugs to be used in anti-cancer therapy with the construction of a nanoparticle platform for targeted delivery of therapeutic nucleic acids”.

The project is funded by grant from Medical Research Agency (Agencja Badań Medycznych – ABM; ABM/2022/6).

SyVento as a CDMO is responsible for GMP technology transfer, optimization and scale-up, manufacturing of GLP batch for toxicology studies, and production of clinical batch for phase I clinical trials.

Biotechna S.A. is an innovative Polish biotechnology company developing next-generation therapies for cancer. The company combines advanced nanotechnology with RNA-based therapeutics to create targeted treatments designed to improve efficacy while minimising side effects.

Core Focus Areas

  • Targeted Nanotechnology
    Biotechna is developing proprietary nanoparticle drug delivery platforms capable of transporting multiple synergistic therapeutic agents directly to cancer cells. This targeted approach aims to maximise treatment effectiveness while reducing off-target toxicity and improving patient safety.
  • siRNA Technology
    The company leverages short interfering RNA (siRNA) technology to selectively silence disease-causing genes. By targeting previously difficult-to-drug molecular pathways, Biotechna seeks to inhibit tumour growth and address key drivers of cancer progression.
  • Oncology Pipeline
    Developing innovative therapies for solid tumours, with current research focused on lung cancer, breast cancer, brain tumours, and melanoma.